Cargando…

Repurposing the β(3)-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial

IMPORTANCE: Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β(3)-adrenergic receptors (β3ARs) may represen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balligand, Jean-Luc, Brito, Dulce, Brosteanu, Oana, Casadei, Barbara, Depoix, Christophe, Edelmann, Frank, Ferreira, Vanessa, Filippatos, Gerasimos, Gerber, Bernhard, Gruson, Damien, Hasenclever, Dirk, Hellenkamp, Kristian, Ikonomidis, Ignatios, Krakowiak, Bartosz, Lhommel, Renaud, Mahmod, Masliza, Neubauer, Stefan, Persu, Alexandre, Piechnik, Stefan, Pieske, Burkert, Pieske-Kraigher, Elisabeth, Pinto, Fausto, Ponikowski, Piotr, Senni, Michele, Trochu, Jean-Noël, Van Overstraeten, Nancy, Wachter, Rolf, Pouleur, Anne-Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512168/ https://www.ncbi.nlm.nih.gov/pubmed/37728907 http://dx.doi.org/10.1001/jamacardio.2023.3003

Ejemplares similares

Rationale and design of a multicentre, randomized, placebo‐controlled trial of mirabegron, a Beta3‐adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3‐left ventricular hypertrophy (Beta3‐LVH)
por: Pouleur, Anne‐Catherine, et al.
Publicado: (2018)

Floppy interatrial septum mimicking an ASD: The role of left atrial pressure
por: Zach, Veronika, et al.
Publicado: (2021)

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
por: Pieske, Burkert, et al.
Publicado: (2017)

Obstructive sleep apnea, hypertension, and obesity: A dangerous triad
por: Belyavskiy, Evgeny, et al.
Publicado: (2019)

Case Report: Assessing the Position of Pacemaker Leads via Transthoracic Echocardiography: Additional Value of the Subcostal En Face View
por: Deichl, Andrea Simone, et al.
Publicado: (2021)

Speckle tracking: distinction of physiologic from pathologic LVH?
por: van der Wall, E. E., et al.
Publicado: (2010)

Fibrosis quantification in Hypertensive Heart Disease with LVH and Non-LVH: Findings from T1 mapping and Contrast-free Cardiac Diffusion-weighted imaging
por: Wu, Lian-Ming, et al.
Publicado: (2017)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

EFFECT of daily antiseptic body wash with octenidine on nosocomial primary bacteraemia and nosocomial multidrug-resistant organisms in intensive care units: design of a multicentre, cluster-randomised, double-blind, cross-over study
por: Meißner, Anne, et al.
Publicado: (2017)

Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study
por: Baka‐Ostrowska, Małgorzata, et al.
Publicado: (2021)

Compelling therapy of LVH: straight (and not-so-straight) inferences from evidence
por: Mehta, Ravi Tejraj, et al.
Publicado: (2019)

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

The effect of intensive hemodialysis on LVH regression and blood pressure control in ESRD patients
por: Darabi, Forough, et al.
Publicado: (2020)

Comparison of feature tracking, fast‐SENC, and myocardial tagging for global and segmental left ventricular strain
por: Bucius, Paulius, et al.
Publicado: (2019)

Nitric oxide metabolites: associations with cardiovascular biomarkers and clinical parameters in patients with HFpEF
por: Piatek, Karsten, et al.
Publicado: (2022)

Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction
por: Maffeis, Caterina, et al.
Publicado: (2022)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
por: Kim, Seo-Yeon, et al.
Publicado: (2023)

ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
por: Kozor, Rebecca, et al.
Publicado: (2016)

Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Left atrial function and maximal exercise capacity in heart failure with preserved and mid‐range ejection fraction
por: Maffeis, Caterina, et al.
Publicado: (2020)

Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure
por: Frydas, Athanasios, et al.
Publicado: (2020)

Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis
por: Morris, Daniel Armando, et al.
Publicado: (2017)

Cardiovalve in mitral valve position—Additional solution for valve replacement
por: Sherif, Mohammad, et al.
Publicado: (2022)

Serum sickness–like reaction associated with mirabegron
por: Tan, Marcus G., et al.
Publicado: (2019)

Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)

Reproducibility study on myocardial strain assessment using fast-SENC cardiac magnetic resonance imaging
por: Giusca, Sorin, et al.
Publicado: (2018)

Defining the optimal temporal and spatial resolution for cardiovascular magnetic resonance imaging feature tracking
por: Backhaus, Sören J., et al.
Publicado: (2021)

The association between BMP4 gene polymorphism and its serum level with the incidence of LVH in hypertensive patients
por: Gu, GL, et al.
Publicado: (2015)

Iron Deficiency Impacts Diastolic Function, Aerobic Exercise Capacity, and Patient Phenotyping in Heart Failure With Preserved Ejection Fraction: A Subanalysis of the OptimEx-Clin Study
por: Gevaert, Andreas B., et al.
Publicado: (2022)

Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study
por: Brosteanu, Oana, et al.
Publicado: (2017)

Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial
por: Verheyen, Nicolas, et al.
Publicado: (2017)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Mirabegron: The most promising adipose tissue beiging agent
por: Bel, Jocelyn S., et al.
Publicado: (2021)

The combined effect of metformin and mirabegron on diet‐induced obesity
por: Zhao, Xin‐Yuan, et al.
Publicado: (2023)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Integrating CVH and LVH metrics into an optimization strategy for the selection of Iris collimator for Cyberknife Xsight lung tracking treatment
por: Xiao, Feng, et al.
Publicado: (2021)

Experimental renal transplantation in rats improves cardiac dysfunction caused by chronic kidney disease while LVH persists
por: Hagmayer, Linda, et al.
Publicado: (2023)

Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
por: Tomaschitz, Andreas, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bg7ju4atmt1aai03n7kmleqh5s